The 2-year therapy effect on femoral atherosclerosis was evaluated in the Cholesterol Lowering Atherosclerosis Study (CLAS), a randomized, placebo-plus-diet-controlled angiographic trial of colestipol-niacin therapy plus diet in men with previous coronary bypass surgery. Different diet compositions were prescribed to enhance the differential in blood cholesterol responses between the two groups. The annual rate of change in computer-estimated atherosclerosis (CEA), a measure of lumen abnormality, was evaluated between treatment groups. A significant per-segment therapy effect was found in segments with moderately severe atherosclerosis (p <0.04) and in proximal segments (p <0.02). When segmental CEA measures were combined into a per-patient score using an adaptation of the National Heart, Lung, and Blood Institute scoring procedure, a significant therapy effect was observed (p <0.02). Total variance of the annual change rate in CEA was as predicted from pilot studies, but measurement variation was larger. The therapy effect observed in femoral arteries, although significant, was less marked than the strong and consistent benefit previously reported for both native coronary arteries and aortocoronary bypass grafts. (Circulation 1991;83:438- 
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Study Groups and Experimental Design
The CLAS study design has been described.'4 Briefly, CLAS was a randomized, angiographic trial testing the therapy effect of colestipol hydrochloride and niacin plus diet (experimental group) versus placebo plus diet (control group) in 162 of 188 randomized nonsmoking men aged 40-59 years who had progressive atherosclerosis and previous coronary bypass surgery (80 men in the experimental group versus 82 in the control group). Both groups received diet intervention with different diet composition to enhance the differential in blood cholesterol responses between the two groups (30-40% decrease in the experimental group, and 7-8% decrease in the control group). The target diet prescribed for the control group included a daily intake of less than 250 mg cholesterol and provided 26% of energy as fat calories, 10% as polyunsaturated fat, and 5% as saturated fat. The target diet prescribed for the experimental group included a daily intake of less than 125 mg cholesterol and provided 22% of energy as fat calories, 10% as polyunsaturated fat, and 4% as saturated fat.
Entry LDL cholesterol= (total cholesterol-HDL cholesterol) -triglycerides/5 Total cholesterol, triglycerides, and HDL cholesterol were measured at each screening visit, at monthly intervals for the first 6 months on treatment, and at 2-month intervals thereafter.
Baseline averages for each blood lipid and lipoprotein were the unweighted values obtained at the first three screening visits. On-trial averages were obtained from values weighted according to the scheduled interval (either 1 or 2 months) between treatment visits.
Angiographic Analysis
Bilateral femoral angiography was performed using radiographic factors previously shown by tests in human cadavers to produce accurate measures of femoral artery pathology.'8 The in vivo reproducibility of femoral atherosclerosis measures was tested in a previous pilot study. '9 In CLAS, coronary, femoral, and cervical artery visualizations were performed in the same sequence at all examinations. A description of the entire procedure has been published,14 and details relevant to femoral visualization are given here.
Patients were fasting and were not premedicated. The right femoral artery (rarely, the left femoral artery) was punctured with a one-piece Cook needle and a J wire was advanced to the descending aorta. Next, a pigtail catheter was introduced into the descending aorta, where it was cleared and connected to pressure recordings. After 1982, an arterial introducer (USCI) was used. Then, 5,000 IU heparin was given through the intra-arterial catheter, which was advanced to the ascending aorta, and cervical angiography was performed.
The pigtail catheter was withdrawn to the abdominal aorta, just above the bifurcation. Next, an image intensifier was positioned above the knee, and the timing of arrival of Renografin 76 to Hunter's canal was established by injecting 4 ml of contrast medium at 30 ml/sec. Femoral angiography was then performed by injecting 40 ml of contrast medium at 30 ml/sec, and films were exposed at a rate of 3 sec`for 5 To find the edges, the gradients of picture intensity were calculated for a sequence of points in each row of the image. The gradient value was obtained with a linear filter that combined image smoothing and differentiation. This filter was implemented as a weighted average of 43 picture points. The window for the first line was set manually. The gradients were weighted to give greater importance to gradients that occurred near the center of the window. The left and right vessel edges were defined as the coordinates of the weighted maximum positive and negative gradients, respectively. Left and right edges were found independently.
At some places along the vessel, such as at the origin of larger branches, the edges were ambiguous and the edge tracking was unreliable. At these places, the computer operator indicated the position of the bad edges with a cursor, and these points were subsequently ignored when measuring vessel characteristics.
Midline calculation. After all valid edges have been found, missing edges due to branches or crossing vessels were temporarily filled in by linear interpolation from the nearest valid edges. The midpoint between the left and right edges for each line was determined, and the set of midpoints was then smoothed using a 401-point averaging filter.
Curvature correction. Curvature of the vessel was estimated by fitting a minimum least-squares straight line to the midline and defining a curvature index (CI) as the root-mean-square difference between this line and the midline points. Segments with CI of more than 10 pixels were straightened by resampling the original digitized image to the vessel midline over the 5-cm film segment plus 100 lines at the top and bottom to allow change in segment length during straightening. This procedure was tested in a random sample of films and found to eliminate outlying values of CEA in curved vessels. Picture elements of each straightened line were obtained using bilinear interpolation. The midline in the straightened image was exactly vertical.
Computer Measures ofAtherosclerosis
Four measures of atherosclerotic lesion characteristics were derived.19,20 The first, the vessel width, was defined as the average difference between the right and left edge coordinates. The second, R(81,97), and third, R(97,321), were roughness measures obtained by comparing the effects of a long and short filter on edge points.18 For example, R(97,321) was obtained from a comparison of a 97-point edge-smoothing filter with a 321-point edge filter.
The fourth measure, computer-estimated atherosclerosis (CEA), was calculated as a (dimensionless) linear function of the tapered lumen 90 (TL90) as follows.14,20 First, a vessel width was computed for each image line, and a least-squares straight line was fit to the sequence of width values as a means of estimating vessel taper. If s is the slope of the line fit to the widths, then (w equals s multiplied by picture lines) is an estimate of the change in vessel width due to taper. The slope computation excluded lines for which the left or right edges were missing. Next, the midline was tilted by one half of w due to taper and then translated to the right until 90% of the righthand edge points lay to the left of the translated midline and 10% to the right. A similar process was applied to the left side of the vessel. The pair of translated midlines comprised the computer estimate of the predisease lumen location. TL90 is defined to be the root-mean-square difference between the detected edge and the tilted translated midlines. This quantity was computed for 5-cm segments as well as for 1-cm subsegments and for each side of a segment. Areas of missing edges were excluded from the computation. Finally, CEA is defined as CEA= -3.34 +0.179TL90 The linear relation between CEA and TL90 was derived through a postmortem study that calibrated the method with 128 5-cm human femoral artery segments. 18 The computer estimate of the prediseased lumen incorporated in CEA is independent of vessel dilation because the location of the left and right computer lumen lines are determined independently of each other. The shape of the computer lumen is derived from the midline of the detected edges, which is independent of vessel dilation. After the lumen shape is determined, it is translated to the left until 10% of the edge points are to the left of the lumen and 90% are to the right. A symmetrical process is used to find the location of the computer lumen on the right. Thus, the locations of the left and right lumens are determined independently of each other and of vessel width.
These calculated maximum likelihood estimates of these data. The expected variation in atherosclerosis change from subject to subject (14.1) and anticipated error of measurement of change per subject (14.4) were of equal magnitude. The overall variance used in the power calculations was V=14.1+14.4/ TV= 17.7, where T of 2 years is the interangiographic interval. Detecting a therapy effect of 40% required a differential of 1.68 CEA units/yr between the two treatment groups.
Extent of Masking
Both study patients and clinic staff were masked to the prerandomization study drug trial lipid responses. Study patients were masked to treatment assignment. During follow-up, clinic personnel were not masked to treatment assignment, and patients and clinic staff were not masked to on-trial lipid values. Evaluation of study outcome measures (panel assessment of coronary status and CEA) were carried out by staff and consultants who were masked to treatment group assignment as well as temporal ordering of angiographic data; this included the angiographer as well as the coronary panel and staff determining femoral CEA.
Statistical Analysis
Analyses of the annual change rate in CEA were performed on both a per-segment and a per-patient basis. For the per-segment analysis, we used the method of Rossner.22 This method permits testing for treatment efficacy on a per-segment basis after adjusting for the within-subject correlation. Analyses were performed overall and within quartiles of baseline CEA and for proximal and distal segments. The per-segment evaluation was part of the original study design.
For the per-patient analysis of CEA, we used an adaptation of the National Heart, Lung, and Blood Institute (NHLBI) scoring procedure. 23 The perpatient analysis was not part of the original analytic plan. The NHLBI scoring procedure, established in 1984, presented an appropriate method for scoring segments to arrive at a per-patient outcome. On the basis of the distribution of the annual change in CEA for both groups, we classified segments as progressing, regressing, or not changing. We classified a segment as regressing if it was less than 1 SD below the mean annual change rate in CEA. A segment progressed if it was greater than 1 SD above the mean annual change rate in CEA. Otherwise, there was no change in the segment. The mean and SD were to be determined empirically from the distribution of the annual change rate in CEA for CLAS patients. We then evaluated overall patient femoral status using the followin,g algorithm. A progressor was defined as a patient with progression in at least one segment and no change in the others. A regressor was defined as a patient with regression in at least one segment and no change in the others. A Seventy-seven patients (of 80) in the experimental group and 75 patients (of 82) plus one patient (of 26) who did not have coronary end point data (and was not included in our previous coronary report3) in the control group had segments that were analyzable at baseline and at 2 years. Table 1 gives a summary of baseline and on-trial determinations of fasting blood lipids. There were no significant differences between the treatment groups at baseline. When comparing the on-trial values between the two treatment groups, large significant differences were found for all lipids (p<0.001). Within the experimental group, statistically significant percent decreases from baseline were found for total cholesterol (26% -percent not shown in Table   1 ), triglycerides (22%), LDL cholesterol (43%), ratio of LDL cholesterol to HDL cholesterol (57%), and ratio of total cholesterol to HDL cholesterol (45%). In addition, the drug and diet therapy significantly increased HDL cholesterol (38%). In the control group, modest yet statistically significant decreases were found for total cholesterol (4%), triglycerides (5%), LDL cholesterol (5%), ratio of LDL cholesterol to HDL cholesterol (6%), and ratio of total cholesterol to HDL cholesterol (5%). HDL cholesterol did not change significantly.
Per-Segment Analysis
The average number of pre/post pairs that were analyzed was 6.8 per patient for the experimental group and 6.9 per patient for the control group. The two treatment groups were on trial for an average of 2.05 (experimental group) and 2.06 years (control group). The two treatment groups showed similar femoral disease at baseline as measured by baseline CEA (Table 2) . Overall, each group exhibited significant progression (p<0.05); although the control group demonstrated slightly larger progression than the experimental group, this was not statistically significant. Table 2 also summarizes CEA change rates for segments categorized into quartiles on the basis of the cumulative distribution of baseline CEA. On the average, for segments with little femoral disease (quartiles 1 and 2), there was significant increase in CEA per year within each treatment group but no differences between treatment groups. For segments with moderate and large femoral disease (quartiles 3 and 4), there was no significant change in CEA per year within each treatment group, although there was a trend toward regression in the experimental group (quartiles 3 and 4) and the control group (quartile 4). For quartile 3 (moderate disease), there was a significant difference between the treatment groups (p<0.04); drug and diet therapy reduced the rate of progression, but placebo and diet therapy did not. The estimates of intersegment correlation ranged from 0.11 to 0.28.
Finally, Table 2 gives a summary of CEA change by distal and proximal segments. Baseline CEA was significantly greater for the distal segments than for the proximal segments (p<O.OOO1). After treatment, there were no significant changes in CEA for the distal segments. For the proximal segments, there was a significant therapy effect (p<0.02), with a significant increase in CEA per year noted in the control group (p<O.OO1).
Per-Patient Analysis
We plotted the distribution of the annual change rate in CEA for all segments in both treatment groups ( Figure 1 ). The mean CEA change rate was 1.0, and the SD was 6.8. We classified a segment as having regressed if the change rate in CEA was less than 1.0-6.8= -5.8. We classified a segment as having progressed if the change rate in CEA was more than 1.0+6.8=7.8. A segment with a change rate in the range (-5.8, 7.8) was regarded as having not changed. We then calculated the overall patient femoral status using the algorithm described above. Change in Femoral CEA FIGURE 1. Bar graph of distribution of annual change rate in femoral segment computer-estimated atherosclerosis (CEA). Mean ±SD CEA change rate was 1.0±6.8. Regressed segments are those with CEA change rate of less than -5.8. Progressed segments are those with CEA change rate of more than 7.8. Segments with CEA change rate between -5.8 and 7.8 were regarded as having not changed. group (21 of 76, or 28%) (p=0.02 using a one-sided Fisher's exact test comparing the rate of regression with that of progression or not changing). On the other hand, 51 of 153 patients (33%) progressed, a smaller proportion being in the experimental group (21 of 77, or 27%) than in the control group (30 of 76, or 39%) (p=0.08 comparing the rate of progression with that of regression or not changing). Analysis of the 2x2 table comparing regressors with progressors (eliminating nonchangers) revealed that the rate of regression was significantly greater in the experimental group (35 of 56, or 63%) than in the control group (21 of 51, or 41%) (p=0.02).
We then stratified by baseline cholesterol levels ( Figure 2 , right panels). For patients with cholesterol of 240 mg/dl or less, 15 of 22 experimental patients (68%) showed regression compared with 11 of 28 control patients (39%) (p<0.04); for patients with cholesterol of more than 240 mg/dl, 20 of 34 experimental patients (59%) showed regression compared with 10 of 23 control patients (43%) (p=NS).
Using these classifications, we compared the other angiographic image processing measures with patient status. Annual changes in R(81,97) and R(97,321) were significantly correlated with progression/regression (p<0.0001), but change in vessel width was not (Table 3) .
We also compared on-trial lipid determinations with patient status (Table 3) . (These analyses were performed after noting that the distribution of age at randomization and baseline lipids were not significantly different across the three groups.) HDL Previous studies. This is the first controlled trial to report a significant per-patient benefit in the femoral artery from blood lipid-lowering therapy. Previous (Tables 2 and 3) . To arrive at a per-patient end point, we applied the classification of the NHLBI Type II study23 to the computer-derived segmental femoral change rates for a per-patient treatment outcome measure that accommodated within-subject variation. CLAS femoral data classified on a three-step NHLBI scale showed a significant drug and diet therapy effect when comparing regressors with progressors ( Figure 2) . A drug and diet therapy effect was also noted for regression/ progression rates for patients with lower baseline cholesterol levels (<240 mg/dl). Because CLAS patients were selected on the basis of previous aortocoronary bypass surgery; had blood lipid levels typical of coronary disease, not hyperlipoproteinemia; had no symptoms of femoral artery disease; and were not tested with clinical measures of blood flow or flow reserve in the legs, it is not possible to relate the CLAS femoral artery outcome to previous femoral angiographic study results. Furthermore, because the diet compositions were different between the two treatment groups, it is not possible from these data to attribute the observed therapy effects to the drug alone, although it is likely that the drug was the primary contributor.
The femoral therapy effect in CLAS appears less marked than the strong and consistent benefit that was observed in both native coronary ous study, and detection of an effect size of 40% required a differential of 1.66 CEA units/yr. A differential effect of 1.8=0.9-(-0.9) CEA units/yr was noted for segments with baseline CEA in the third quartile (Table 2) but not in other quartiles or in all patients combined. In addition, a differential effect of 1.9=2.6-(0.7) was noted for proximal segments.
The larger measurement variation encountered in CLAS may be due to differences in radiographic technique between CLAS and our pilot study.'0 For CLAS angiograms, both legs were filled simultaneously with contrast medium injected into the aorta. In our pilot study, contrast medium was injected through a needle into one femoral artery. Electrocardiographic gating was not performed in either study. Recent experiments in Sweden in which the performance of femoral angiography has been rigorously evaluated in duplicate procedures at 10-minute intervals indicate that the precision of measurement is significantly improved by exposures gated against the cardiac cycle.24
Femoral Artety Disease Risk Factors
Criqui and coworkers,25 using noninvasive atherosclerosis-related flow measures, found epidemiological evidence that disease in large femoral vessels was significantly associated with cigarette pack-years, systolic blood pressure, and fasting blood glucose but not with blood lipoprotein levels, except for a marginal association of HDL cholesterol with severe disease.25 CLAS patients were nonsmokers and normotensive. In CLAS, therapy reduced blood lipid levels that may be principal coronary risk factors. Thus, the femoral outcome in CLAS is in accord with Criqui et al's findings.
It is possible that the significantly higher levels of HDL cholesterol in femoral regression patients compared with femoral progression patients may be an indication of differences between femoral and coronary arteries because HDL cholesterol was not found to have a significant effect in the coronary arteries.26 However, it is important to note that different measures of atherosclerosis change have been used in the two vessel beds (e.g., CEA change in femoral arteries and global coronary change score from human panelists in coronary vessels). We are now evaluating CLAS coronary angiograms with computerized image processing to obtain more equivalent measures for additional between-vessel comparisons of risk factor effects.
Summary
A significant per-patient therapy effect has been observed with colestipol-niacin-plus-diet therapy in the femoral arteries. Total variance of CEA change in CLAS was as predicted from pilot studies, but measurement variation was larger. A per-segment analysis demonstrated a significant therapy effect in segments with moderately severe atherosclerosis and in proximal femoral segments.
